Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

OCTOBER 15, 2021

DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention. Poster Number: INFO37.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

DECEMBER 26, 2021

. “With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

DECEMBER 9, 2021

. “The FDA is supportive of our plans to develop regulated devices that would allow the use of novel analyses of multimodal data to capture, model, and map outputs that, if cleared, could be useful to clinicians and patients in the delivery of psychedelic and other perception-altering substances.” Media Contact: media@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

AUGUST 21, 2019

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

MMJ Recs

DECEMBER 22, 2023

Public discourse became more nuanced, with patients and advocacy groups championing the cause of medical marijuana as a legitimate and effective treatment option. Another influential factor is the growing emphasis on individual autonomy and patient choice in healthcare.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Adding KWC will ensure our existing patients and many more in the future will receive the best medical treatment and care.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

DECEMBER 9, 2021

MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Media Contact nuelife@derris.com. “We are proud to support the profound research of these organizations,” continued Mr. Cappello. ” About Nue Life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Media Releases. Track Inquiry.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. media enquiries.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

JULY 7, 2021

Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., Media Contact: Will Johnson. inhibitors are the most prescribed drugs by revenue globally, at $40 billion per year. Chief Scientific Officer for MyMD. Investor Contact: Robert Schatz.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

CannaMD

NOVEMBER 6, 2019

Today, both patient experience and modern scientific research support claims of medical marijuana’s effectiveness for pain management. Questions included any changes in personal levels of opioid use when marijuana was also used, and the reasons why patients were substituting marijuana for prescription pain medications.

Marijuana 87

Marijuana Patients Clinical Trials Data 87

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. For further information: For media inquiries: Contact Jonathan McGuire, Assistant Vice President, Corporate Communications, Horizons ETFs Management (Canada) Inc.,

Data 105

Data Clinical Trials Decriminalization Hemp 105

The Cannigma

JULY 1, 2022

These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”. Media: Liz Melone. 212-362-1200.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 11 × 11. 15 × 15.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Blunt Truth

AUGUST 13, 2019

The FDA is also meeting with other federal agencies and state counterparts, trade organizations, and patient groups in a quest for data. On Friday, July 26, 2019, Curaleaf responded, noting that it has taken steps to review all inaccurate statements about CBD products from their websites and social media platforms.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JULY 23, 2019

It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. required to provide other warnings that may be needed by the commission. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

NOVEMBER 24, 2019

Dr. Griffiths and Dr. Johnson will be speaking at Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks conference in Washington DC. The award is in part based on his media appearances regarding psychedelic research. ANOREXIA NERVOSA. ALZHEIMER’S DISEASE. Upcoming Events.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Cannabis Law Report

JULY 23, 2019

LGC and its investors will benefit from a substantial competitive advantage through their knowledge and clinical trial capacity and its capacity to handle the regulatory compliance process for pharmaceuticals and food products,” said Mazen Haddad, CEO of LGC. Media – Kellie Coppin: kcoppin@renmarkfinancial.com.

Pharmaceutical 45

Pharmaceutical Seed-To-Sale Compliance Compliance 45

The Cannigma

JUNE 24, 2021

The constant distractions, notifications, and social media outrages of the day can also boost your anxiety and stress, and make it much harder to just live in the moment. Nausea and vomiting — cannabis has long been seen as a potential supportive treatment option for cancer patients undergoing chemotherapy.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

SEPTEMBER 29, 2021

Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com. GREENWOOD VILLAGE, Colo. &

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

FloridaMarijuana.net

AUGUST 13, 2018

There are a variety of treatment options to help patients cope with and heal from anxiety disorders. Medical marijuana is another option for patients suffering from anxiety. Even mainstream media has delved into the medicinal properties of cannabis and the science-based culture that cannabis heals.

Marijuana 145

Marijuana Patients Clinical Trials Conditions 145

Cannabis Law Report

OCTOBER 22, 2021

SPL026 entered clinical trials at the beginning of 2021 and this designation marks an important step forward towards an accelerated drug approval pathway for bringing the benefits of SPL026 to market for patients suffering with MDD.”. Media Relations Contact. Key partnering stakeholders include the MHRA, the U.K.’s

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JULY 8, 2021

“Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.” Clomiphene will then be added to the regimen for up to 24 patients to rule out toxicity.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Project CBD

FEBRUARY 28, 2023

In December 2021, Leafreport, an online CBD resource owned by Empire Media Network, published the results of analyses of 221 CBD products it sent to third-party laboratories for testing. Available at: www.fda.gov/media/131878/download. 17 Excerpted from HerbalGram , the quarterly publication of the American Botanical Council.

CBD 144

CBD Seed-To-Sale Food Access 144

FloridaMarijuana.net

OCTOBER 19, 2018

Some patients find success with pharmaceuticals and talk-therapy. In addition to these medical interventions, Medical marijuana may also be beneficial to clinically depressed patients. Medical marijuana is another option for patients suffering from anxiety. Depression can be treated several ways.

Marijuana 189

Marijuana Research and Development Patients Clinical Trials 189

CannaMD

MARCH 8, 2021

If you’re a Florida medical marijuana patient, chances are you’ve heard of House Bill 1455 – a proposed bill making its rounds through the state legislature as we speak. But, behind the outrage, lies a larger conversation regarding free speech, fair pricing, and the sanctity of the physician-patient relationship.

THC 116

THC Research and Development Treatment Patients 116